Canada Markets closed

ChemoCentryx, Inc. (CCXI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
19.20+0.03 (+0.16%)
At close: 04:00PM EDT
19.00 -0.20 (-1.04%)
After hours: 05:43PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close19.17
Open19.14
Bid19.20 x 900
Ask19.20 x 900
Day's Range18.75 - 20.36
52 Week Range9.53 - 42.16
Volume1,177,927
Avg. Volume1,454,290
Market Cap1.345B
Beta (5Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference

    SAN CARLOS, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022 at 12:30 p.m. ET. The conference will be held at the Fontainebleau Miami Beach Hotel in Miami, FL. A live audio webcast of the presentations can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com.

  • GlobeNewswire

    ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis

    SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and research into the burden of glucocorticoid use in ANCA-associated vasculitis. ATS 2022 (American Thoracic Society), May 15-17, San Francis

  • GlobeNewswire

    ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights

    -- Five-fold increase in net sales of TAVNEOS® (avacopan) quarter-over-quarter with $5.4 million in Q1 2022 -- -- Marked growth in key performance indicators (Q1 2022 to Q4 2021 comparison): - 195% TAVNEOS new Patient Start Forms - 275% Unique Prescribers - 308% Patients on Drug -- -- Global expansion continues with approvals in European Union (EU) and Canada; $45 million milestone received from TAVNEOS EU approval -- -- Positive Phase I data on pharmacokinetics (PK) and pharmacodynamics (PD) in